RAC - Charts & Price Action, page-5940

Busy 12-24 months coming with a particularly busy end to this year. We will have 4 trials underway by end of Q3 with periodic dosing updates. Two more trials are planned to start in early 2022.

There's also 3 new preclinical activities underway and a 4th due to start. We are also waiting for publication of other preclinical work for Breast and Ovarian Cancer ( results previously released ).

Armed with more data RACE plan to start marketing themselves to Big Pharma by the end of this calendar year.

Important context is the history of the drug ( we know from historic trials and the Israel trial completed in 2020 that the drug is safe and effective ). This bodes well for upcoming trials.

The 3 x FTO trials below are actually at much lower doses than used historically so there should be no risk of safety issues ( Bisantrene is already know for strong cardiac safety at the higher doses used historically ).

FTO looks like it parallels the PD-1 sector but will be a much bigger market ( and RACE are years ahead of competition ).